HUM Q2 Deep Dive: Pharmacy Strength, Medicaid Expansion, and Guidance Lift

Health insurance company Humana (NYSE:HUM) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 9.6% year on year to $32.39 billion. The company’s full-year revenue guidance of $128 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $6.27 per share was 6.9% above analysts’ consensus estimates.

Is now the time to buy HUM? Find out in our full research report (it’s free).

StockStory’s Take

Humana delivered a second quarter that outpaced Wall Street’s expectations, with management highlighting CenterWell Pharmacy’s strong performance and stable medical cost trends as key drivers. CEO James Rechtin attributed the positive results to “better-than-expected individual Medicare Advantage membership” and a rebound of members who returned to Humana after trying other plans. Management also pointed to efforts streamlining the prior authorization process and investments in improving the member experience as contributors to the quarter’s outcomes.

Looking ahead, Humana’s updated full-year outlook is shaped by continued momentum in CenterWell Pharmacy and ongoing investments in clinical excellence and operational transformation. CFO Celeste Mellet indicated that an additional $100 million will be deployed to initiatives such as pairing in-home visits with virtual health, as well as technology-driven back office improvements. Management believes these steps will support more reliable margins and prepare the company for evolving regulatory and competitive landscapes, particularly in Medicare Advantage and Medicaid.

Key Insights from Management’s Remarks

Management attributed Q2’s outperformance to pharmacy segment growth, improved member retention, and a disciplined approach to benefits and cost management.

• CenterWell Pharmacy momentum: CenterWell Pharmacy exceeded expectations due to higher direct-to-consumer volumes and increased access to specialty drugs through new industry partnerships. Management cited partnerships with companies such as Ro and Weight Watchers, enabling expansion into GLP-1 therapies, and highlighted that “direct-to-consumer momentum” is expected to continue supporting results.

• Medicare Advantage member recapture: Humana saw a higher-than-anticipated rate of former members returning during the open enrollment period, which CEO James Rechtin explained is associated with improved year-one economics, as these members are already familiar with Humana’s care model and can be better engaged clinically.

• Medicaid expansion and performance: The company expanded its Medicaid footprint to 10 states, with 3 more pending. Management emphasized that its Medicaid book, which is skewed toward long-term support services (LTSS) populations in non-expansion states, is less exposed to industry-wide cost pressures and regulatory changes. President George Renaudin added that Humana’s value-based provider network differentiates its Medicaid performance.

• Benefit redesign and cost discipline: Humana executed significant benefit reductions and market exits over the past two years, focusing on aligning product offerings with funding trends. This has resulted in a gap relative to peers’ benefit value, but management believes the changes have led to a more sustainable membership mix and improved profitability.

• Back office transformation: The company began implementing a multi-year transformation of its operating model, including an early retirement program and expanded outsourcing of shared services. Rechtin stated these changes are intended to create a more nimble, technology-enabled organization that can better respond to consumer needs.

Drivers of Future Performance

Humana’s guidance for the rest of the year is anchored by ongoing pharmacy growth, disciplined cost management, and broader operational transformation initiatives.

• Pharmacy and specialty drug growth: Management expects continued strength from CenterWell Pharmacy, supported by direct-to-consumer channels and new specialty drug partnerships, to drive both top-line growth and margin expansion. The company also highlighted sustained demand for GLP-1 therapies and broader specialty drug access.

• Medicaid and Medicare Advantage stability: The company anticipates stable trends in both Medicaid and Medicare Advantage, given its focus on long-term support services and disciplined benefit design. Management stated that its state footprint and value-based network structure make its Medicaid business less susceptible to industry-wide trend issues.

• Operational transformation and investment: Humana is deploying additional investments into member retention, clinical technology, and operational efficiency, aiming to improve outcomes and enable scalable growth. Management noted that the transformation will be gradual, with a focus on balancing cost savings and service improvements.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will monitor (1) the pace and impact of Humana’s operational transformation initiatives, (2) progress in Medicaid expansion, especially as new state contracts go live, and (3) sustained growth in CenterWell Pharmacy, particularly in specialty and direct-to-consumer models. Developments in regulatory policy and the Medicare Advantage landscape will also be crucial signposts for tracking the company’s execution.

Humana currently trades at $266.61, up from $232.84 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.